A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...
BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...
How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback